GH Research is developing GH001, an inhalable mebufotenin therapy targeting treatment-resistant depression. The company reported strong Phase 2b clinical trial results and plans to start a global Phase 3 program in 2026. GH001 is notable for its rapid onset and short psychedelic experience, which may offer advantages over competitors. Despite uncertainties about real-world performance, GH Research is viewed as undervalued due to the large market potential and significant unmet medical needs in depression treatment.
The global helium market, valued at $5.03 billion in 2025, is projected to grow to $8.59 billion by 2035 with a CAGR of 5.47%. Growth is fueled by rising demand in healthcare for MRI superconducting magnet cooling and expanding semiconductor manufact...
Defiance ETFs has introduced the Defiance Memory UCITS ETF (DRAM), the first memory-focused ETF in Europe, listed on Xetra and Borsa Italiana, with plans for London Stock Exchange. This ETF targets companies involved in memory semiconductors and data...
Defiance ETFs has launched the first Memory UCITS ETF (DRAM) in Europe, focusing on companies involved in memory semiconductors and data storage systems. This ETF offers European investors access to the growing memory sector driven by AI, cloud compu...
Defiance ETFs has introduced the Defiance Memory UCITS ETF (DRAM), the first European ETF focused on semiconductor memory and data storage companies. This ETF provides European investors exposure to a sector driven by rising demand from AI, cloud com...
Defiance ETFs has launched the first Memory UCITS ETF in Europe, named Defiance Memory UCITS ETF (DRAM), providing exposure to companies involved in semiconductor memory and data storage systems. This ETF addresses growing demand driven by AI, cloud ...
